Cardio Diagnostics Holdings (CDIO) EBITDA Margin (2022 - 2026)

Cardio Diagnostics Holdings has disclosed EBITDA Margin across 5 years of filings, most recently posting 27950.5% for Q2 2026.

• In Q2 2026, EBITDA Margin fell 549299.0% year-over-year to 27950.5%; the TTM figure through Jun 2026 stood at 44690.68% (down 1272970.0% YoY), while the FY2025 annual figure was 43737.46%, down 1975959.0% from the prior year.
• EBITDA Margin came in at 27950.5% for Q2 2026 at Cardio Diagnostics Holdings, up from 66598.4% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 14398.71% in Q3 2023 to a low of 250321.79% in Q4 2022.
• Average EBITDA Margin over 5 years is 66483.62%, with a median of 31323.86% recorded in 2023.
• Year-over-year, EBITDA Margin jumped 22128228 bps in 2023 and sank 14735856 bps in 2025.
• Over 5 years, EBITDA Margin stood at 250321.79% in 2022, then soared by 88 bps to 29039.51% in 2023, then retreated by 16 bps to 33608.2% in 2024, then slipped by 22 bps to 41159.55% in 2025, then soared by 32 bps to 27950.5% in 2026.
• Per Business Quant data, the three most recent EBITDA Margin figures were 27950.5% in Q2 2026, 66598.4% in Q1 2026, and 41159.55% in Q4 2025.